MREO (Mereo BioPharma Group) FFO


MREO Mereo BioPharma Group PLC MREO
19 GF Score
Price $0.33
! 1 Warning Sign
View Full Analysis

What is Mereo BioPharma Group FFO?

FFO (Funds from operations) only applies to REITs.

MREO
19GF Score
Mereo BioPharma Group PLC MREO
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mereo BioPharma Group Business Description

Other Exchanges 0A9G:UKMAH0:Germany
Address One Cavendish Place, 4th Floor, London, GBR, W1G 0QF
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
19GF Score

Get the complete analysis for MREO

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.33
Price